{"denoms":[{"counts":[{"groupId":"BG000","value":"411"},{"groupId":"BG001","value":"416"},{"groupId":"BG002","value":"827"}],"units":"Participants"}],"groups":[{"description":"Participants with EC received lenvatinib 20 mg orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study.","id":"BG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"},{"description":"Participants with EC received either doxorubicin 60 milligrams per square meter (mg/m\\^2) intravenously, every 3 weeks, in each 21-day treatment cycle, or paclitaxel 80 mg/m\\^2 intravenously, weekly (3 weeks on/1 week off), in each 28-day treatment cycle. Participants continued to receive treatment until a lifetime cumulative dose of 500 mg/m\\^2 doxorubicin, a maximum dose of paclitaxel per standard of care, or until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.","id":"BG001","title":"Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.1","value":"63.2"},{"groupId":"BG001","spread":"9.2","value":"63.8"},{"groupId":"BG002","spread":"9.1","value":"63.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"In utero"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Preterm newborn infants (gestational age < 37 wks)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Newborns (0-27 days)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Infants and toddlers (28 days-23 months)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Children (2-11 years)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Adolescents (12-17 years)"},{"measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"410"}],"title":"Adults (18-64 years)"},{"measurements":[{"groupId":"BG000","value":"205"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"415"}],"title":"From 65-84 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"85 years and over"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"411"},{"groupId":"BG001","value":"416"},{"groupId":"BG002","value":"827"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"132"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"309"},{"groupId":"BG001","value":"288"},{"groupId":"BG002","value":"597"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"98"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"177"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"31"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"261"},{"groupId":"BG001","value":"247"},{"groupId":"BG002","value":"508"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"20"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"79"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"246"},{"groupId":"BG001","value":"241"},{"groupId":"BG002","value":"487"}],"title":"0 = Fully active; no performance restrictions"},{"measurements":[{"groupId":"BG000","value":"165"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"340"}],"title":"1 = Limited activity, ambulant, can-do light work"}]}],"description":"The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care; 3, capable of limited self-care; 4, completely disabled; and 5, dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) performance status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"363"}],"title":"Participants with pelvic radiation"},{"measurements":[{"groupId":"BG000","value":"235"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"464"}],"title":"Participants without pelvic radiation"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior history of pelvic radiation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"234"},{"groupId":"BG001","value":"240"},{"groupId":"BG002","value":"474"}],"title":"Region 1"},{"measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"176"},{"groupId":"BG002","value":"353"}],"title":"Region 2"}]}],"description":"Participants in region 1 were included from Europe,USA,Canada,Australia,New Zealand,Israel. Participants in region 2 were included from rest of the world.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic region","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"346"},{"groupId":"BG001","value":"351"},{"groupId":"BG002","value":"697"}],"title":"Proficient MMR (pMMR)"},{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"130"}],"title":"Deficient (dMMR)"}]}],"description":"The mismatch repair system (MMR) is a crucial mechanism in DNA repair that identifies and corrects errors that occur during DNA replication and recombination. pMMR indicates that the MMR system is functioning properly, which is advantageous for maintaining genomic stability and reducing mutation accumulation. In contrast, dMMR signifies a deficiency in the MMR system, leading to increased mutation rates and a higher risk of tumorigenesis. pMMR and dMMR were based on actual MMR status defined by immunohistochemistry (IHC) performed on tumor tissue.","paramType":"COUNT_OF_PARTICIPANTS","title":"Mismatch repair (MMR) status","unitOfMeasure":"Participants"}],"populationDescription":"The Intention-to-treat (ITT) population included all randomized participants."}